1 not yet recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Recurrent Endometrial Cancer: new trials by email Literature Review of Recurrent Endometrial Cancer trials Research Report on Recurrent Endometrial Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years - Endometrial Adenocarcinoma, Metastatic Endometrial Cancer | Phase 3 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-10-01 | 2026-10-15 |
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Neoplasms (1) · Neoplasms by Site (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Uterine Diseases (1) · Uterine Neoplasms (1)
UNC Lineberger Comprehensive Cancer Center (1)
United States (1)